Table 1
Treatment regimen
Ara-C indicates cytarabine arabinoside; B, bortezomib; IT, intrathecal therapy; ITA, IT Ara-C; ITM, IT methotrexate; ITT, IT triple therapy; PEG, Peg-asparaginase; and V, vincristine.
Treatment regimen
Ara-C indicates cytarabine arabinoside; B, bortezomib; IT, intrathecal therapy; ITA, IT Ara-C; ITM, IT methotrexate; ITT, IT triple therapy; PEG, Peg-asparaginase; and V, vincristine.
